Combination of interferon alfa-2b and ribavirin in relapsed or nonresponding chronic hepatitis C patients following interferon therapy

  • Laurentius A. Lesmana
  • Unggul Budihusodo
  • Nurul Akbar
  • Ali Sulaiman
  • Sjaifoellah Noer
  • Inge A. Kristanti
  • Rianto Setiabudy
Abstract viewed: 895 times
PDF downloaded: 226 times

Abstract

Twenty six patients (pts) with chronic hepatitis C (CHC) who reLapsed or non-responded following.interferon (IFN) therapy were given lFN alfa-2b 3   MIU three times a week for 48 weeks in combination with Ribavirin 800-1000 mg daily 2I (80,8%) of the 26.pts completed the study consisted of 12 relapsers and 9 non-responders. Five pts dropped out due to drug adverse events in three pts and non-drug related reason in the other two. In the relapsed group complete response, relapse and sustained response rates were obtained in 9/12(75%), 2/2 (16,5%) and 7/12(58,3%) pts respectively. In the non- responding group, these figures were 3/9 (33,3%), 1/9(I1,1%), and 2/9(22,2%) pts, respectively. The most frequent adverse event was flu-like syndrome, which was found in 18 pts (85,7%). Combination therapy of IFN alfa-2b and ribavirin may induce sustained virological response in relapsed and non-responding CHC patients. This combination therapy is more effective for relapsers compared to for non-responders. (Med J Indones 2001; 10: 214-8)

Keywords: Chronic hepatitis C, combination therapy, interferon, ribavirin

Published
2001-11-01
How to Cite
1.
Lesmana LA, Budihusodo U, Akbar N, Sulaiman A, Noer S, Kristanti IA, Setiabudy R. Combination of interferon alfa-2b and ribavirin in relapsed or nonresponding chronic hepatitis C patients following interferon therapy. Med J Indones [Internet]. 2001Nov.1 [cited 2020Oct.21];10(4):214-8. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/37
Section
Clinical Research

Most read articles by the same author(s)

1 2 > >>